1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Novavax, Inc.
  6. News
  7. Summary
    NVAX   US6700024010

NOVAVAX, INC.

(NVAX)
  Report
Delayed Nasdaq  -  05/18 04:00:00 pm EDT
52.11 USD   +0.31%
05/16Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
AQ
05/11TRANSCRIPT : Novavax, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-2022 05:20 PM
CI
05/11SECTOR UPDATE : Health Care Stocks Edging Lower Ahead of Wednesday Close
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

JPMorgan Adjusts Novavax's Price Target to $209 from $172, Keeps Neutral Rating

12/21/2021 | 01:26pm EDT


ę MT Newswires 2021
All news about NOVAVAX, INC.
05/16Novavax Files for Emergency Use Authorization of COVID-19 Vaccine in Taiwan
AQ
05/11TRANSCRIPT : Novavax, Inc. Presents at Bank of America 2022 Healthcare Conference, May-11-..
CI
05/11SECTOR UPDATE : Health Care Stocks Edging Lower Ahead of Wednesday Close
MT
05/11SECTOR UPDATE : Health Care Stocks Still Hanging on for Small Advance
MT
05/11B. Riley Lowers Novavax's Price Target to $181 from $203, Keeps Buy Rating
MT
05/10Wall St slips in choppy trading ahead of inflation data
RE
05/10GLOBAL MARKETS LIVE : Bayer, Sony, AMC, Peloton, Tesla...
05/10Novavax Reports Higher Q1 Results; Shares Slump
MT
05/10WALL STREET STOCK EXCHANGE : A little respite for Wall Street
05/10SECTOR UPDATE : Health Care Stocks Climb Premarket Tuesday
MT
More news
Analyst Recommendations on NOVAVAX, INC.
More recommendations
Financials (USD)
Sales 2022 4 285 M - -
Net income 2022 1 969 M - -
Net cash 2022 2 508 M - -
P/E ratio 2022 2,18x
Yield 2022 -
Capitalization 4 072 M 4 072 M -
EV / Sales 2022 0,36x
EV / Sales 2023 0,22x
Nbr of Employees 1 541
Free-Float 99,0%
Chart NOVAVAX, INC.
Duration : Period :
Novavax, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends NOVAVAX, INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 52,11 $
Average target price 174,83 $
Spread / Average Target 236%
EPS Revisions
Managers and Directors
Stanley C. Erck President, Chief Executive Officer & Director
James Patrick Kelly Chief Financial Officer, Treasurer & Executive VP
James F. Young Chairman
Gregory M. Glenn President-Research & Development
Biegie Lee Chief Information Officer & Senior Vice President
Sector and Competitors
1st jan.Capi. (M$)
NOVAVAX, INC.-63.58%4 059
MODERNA, INC.-45.78%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-30.08%39 122
SEAGEN INC.-7.50%26 976
ICON PUBLIC LIMITED COMPANY-34.37%17 002